@article {1309966,
	title = {A case of Graves{\textquoteright} ophthalmopathy associated with pembrolizumab (Keytruda) therapy},
	journal = {J AAPOS},
	year = {2018},
	month = {2018 Apr 04},
	abstract = {We present the first reported case of Graves{\textquoteright} orbitopathy induced by pembrolizumab, a new FDA-approved drug used for the treatment of multiple refractory solid tumors and classic Hodgkin lymphoma. Pembrolizumab elicits T-lymphocyte proliferation; we suspect that thyroid eye disease may result in some cases.},
	issn = {1528-3933},
	doi = {10.1016/j.jaapos.2018.01.006},
	author = {Park, Ella S Y and Rabinowits, Guilherme and Hamnvik, Ole-Petter R and Dagi, Linda R}
}
